Innate Pharma SA ( (FR:IPH) ) has issued an update.
Innate Pharma S.A. announced that it will hold its annual general meeting of shareholders on May 22, 2025, at its headquarters in Marseille, France. The meeting will include a live broadcast and a guided tour of the company’s laboratories. This event is significant for stakeholders as it provides an opportunity to engage with the company’s strategic direction and developments, potentially impacting its market positioning and investor relations.
More about Innate Pharma SA
Innate Pharma S.A. is a global biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates, and monoclonal antibodies. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca to advance cancer treatment innovations.
YTD Price Performance: -50.0%
Average Trading Volume: 1,075
Technical Sentiment Signal: Strong Buy
Current Market Cap: $165M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.